-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

Benzinga·11/05/2026 20:05:47
Listen to the news
Leerink Partners analyst Daina Graybosch maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $46 to $49.